CASI Pharmaceuticals (CASIF)
OTHER OTC:CASIF
Top Page
CASI Pharmaceuticals
(OTC:CASIF)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.96
▼(-9.43% Downside)
Action:UpgradedDate:01/09/26
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Pipeline advancement (CID-103)
Advancing CID-103 into Phase 1 studies and running parallel ITP work materially strengthens CASI's long-term growth prospects by building a diversified, clinical-stage pipeline. Successful development would create new commercial opportunities beyond legacy oncology sales and reduce single-product dependency.
Negative Factors
Loss of China commercial access (FOLOTYN)
Regulatory denial and halted FOLOTYN sales in China eliminate a material revenue stream and fracture the company’s commercial footprint in a large market. This structural loss pressures top-line sustainability, complicates partner relationships, and may force asset divestiture or prolonged legal disputes.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline advancement (CID-103)
Advancing CID-103 into Phase 1 studies and running parallel ITP work materially strengthens CASI's long-term growth prospects by building a diversified, clinical-stage pipeline. Successful development would create new commercial opportunities beyond legacy oncology sales and reduce single-product dependency.
Read all positive factors
CASI Pharmaceuticals (CASIF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.24M
Dividend YieldN/A
Average Volume (3M)219.83K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth26.20%
EPS Growth-42.26%
CountryUS
Employees233
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding15,492,681
10 Day Avg. Volume60,876
30 Day Avg. Volume219,829
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)23.45
Price to Sales (P/S)1.52
P/FCF Ratio-1.47
Enterprise Value/Market Cap7.45
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit1.73
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.41
Revenue Forecast (FY)$70.35M
CASI Pharmaceuticals Business Overview & Revenue Model
Company Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation ...
How the Company Makes Money
CASI Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, including sales from its oncology therapies. The company may also earn income through licensing agreements, partnerships, and collaborat...
CASI Pharmaceuticals Financial Statement Overview
Summary
Income Statement
37
Negative
Balance Sheet
45
Neutral
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.85M | 28.54M | 33.88M | 43.11M | 30.17M | 15.14M |
| Gross Profit | 9.61M | 11.15M | 20.05M | 27.28M | 17.61M | 5.63M |
| EBITDA | -41.37M | -34.87M | -21.54M | -24.07M | -33.40M | -31.35M |
| Net Income | -49.38M | -39.26M | -26.94M | -41.01M | -36.65M | -48.29M |
Balance Sheet | ||||||
| Total Assets | 24.46M | 53.67M | 75.27M | 96.23M | 138.30M | 127.73M |
| Cash, Cash Equivalents and Short-Term Investments | 4.68M | 16.09M | 30.77M | 51.34M | 48.57M | 66.37M |
| Total Debt | 18.86M | 22.14M | 21.24M | 1.34M | 4.33M | 3.20M |
| Total Liabilities | 53.05M | 51.82M | 51.10M | 29.30M | 30.34M | 24.16M |
| Stockholders Equity | -28.59M | 1.85M | 24.16M | 44.57M | 84.50M | 81.54M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -29.46M | -22.21M | -26.70M | -42.34M | -45.21M |
| Operating Cash Flow | 0.00 | -29.22M | -19.97M | -21.09M | -26.84M | -25.89M |
| Investing Cash Flow | 0.00 | 11.24M | -9.67M | 31.16M | -20.69M | -20.72M |
| Financing Cash Flow | 0.00 | 15.43M | -907.00K | -3.27M | 29.64M | 47.15M |
CASI Pharmaceuticals Technical Analysis
Negative
1.06
Price Trends
0.42
Negative
0.69
Negative
1.20
Negative
Market Momentum
-0.07
Negative
38.24
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASIF, the sentiment is Negative. The current price of 1.06 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.42, and below the 200-day MA of 1.20, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 38.24 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CASIF.
CASI Pharmaceuticals Risk Analysis
CASI Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. CASI Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CASI Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $2.24M | -0.61 | ― | ― | 26.20% | -42.26% | |
46 Neutral | $19.99M | -17.14 | 354.21% | ― | 13.56% | 52.92% | |
46 Neutral | $2.73M | -0.38 | -489.66% | ― | 8.52% | 79.51% | |
46 Neutral | $13.98M | -1.17 | ― | ― | ― | 79.31% | |
43 Neutral | $4.38M | -1.58 | -79.47% | ― | -99.97% | 35.59% |
* Healthcare Sector Average
CASIF
CASI Pharmaceuticals
0.14
-1.81
-92.62%
CRIS
Curis
0.50
-0.67
-57.35%
GOVX
GeoVax Labs
1.23
-24.27
-95.18%
MBRX
Moleculin Biotech
2.62
-17.37
-86.90%
PULM
Pulmatrix
1.20
-4.20
-77.78%
CASI Pharmaceuticals Corporate Events
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
Jan 22, 2026
On January 22, 2026, CASI Pharmaceuticals reported that China’s National Medical Products Administration formally rejected its May 2025 application to renew the Import Drug Registration License for FOLOTYN®, following earlier correspond...
CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing
Jan 13, 2026
On January 13, 2026, CASI Pharmaceuticals announced it had closed the second tranche of its previously arranged US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He, issuing a new US$5 mil...
CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing
Dec 31, 2025
On December 30, 2025, CASI Pharmaceuticals announced that it had closed the first tranche of a US$20 million convertible note financing, issuing a US$5 million note to ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He. The three-ye...
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026
Dec 23, 2025
On December 23, 2025, CASI Pharmaceuticals announced that a Nasdaq Hearings Panel granted the company an extension to remain listed on the Nasdaq Capital Market, provided it regains compliance with the Market Value of Listed Securities requirement...
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study
Dec 11, 2025
On December 11, 2025, CASI Pharmaceuticals announced a $20 million convertible note financing agreement with ETP Global III Fund LP to support a Phase 1 study in China for renal allograft antibody-mediated rejection (AMR). This investment, structu...
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman
Nov 19, 2025
On November 19, 2025, CASI Pharmaceuticals announced a significant change in its board governance with the appointment of James Huang as the Non-Executive Chairman of the Board, effective November 17, 2025. This move is part of a strategic effort ...
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal
Nov 14, 2025
On November 14, 2025, CASI Pharmaceuticals announced its third-quarter 2025 business and financial results, highlighting ongoing advancements in its CID-103 clinical program. The company is preparing for a Phase 1 study in the U.S. for renal allog...
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination
Nov 10, 2025
CASI Pharmaceuticals announced that it received a delisting determination from Nasdaq due to its market value of listed securities falling below the minimum requirement for an extended period. The company has appealed the decision and is working o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.